Objective To observe the therapeutic effect of trimetazidine to treat patients with chronic heart failure( CHF). Before and after treatment, monitoring changes of serum brain peptide(BNP) and interleukin 6(IL-6) ,so as to provide theoretical support for clinical work. Method Choose 76 cases of our hospital treatment in patients with CHF,randomly divided into observation group and control group, both groups contains 38 cases each. Control group with routine treatment only, the observation group in conventional treatment on the basis of add with trimetazidine as 20 mg,three timea/d,a total of 12 weeks, observing both groups before and after treatment, changes of cardiac function and real difference between BNP and IL-6.. Results The total effective rate of the observation group was higher than the control group,two groups of serum BNP,IL-6 expression decreased,but the decline value of observation group was significantly higher than that of control group. Conclusion On the basis of routine therapy combined with trimetazidine treat CHF patients,clinical efficacy is obvious, also, dwon regulate on serum BNP,IL-6 expression effectively,no marked adverse reaction. It is adaptable to clinical application.%目的:观察曲美他嗪治疗慢性心力衰竭(CHF)患者的疗效,并同时监测治疗前后血清脑钠肽(BNP)和白细胞介素-6(IL-6)的改变,以期为临床工作提供理论支持.方法:选择我院治疗的76例CHF患者,随机分成观察组和对照组各38例,对照组采用常规治疗,观察组在常规治疗基础上加用曲美他嗪20mg,3次/d,共12周,观察治疗前、后两组患者心功能改变情况及血清中BNP、IL-6的差异.结果:观察组总有效率明显高于对照组,两组血清BNP、IL-6的表达均下降,但观察组的下降值明显高于对照组.结论:在常规治疗基础上加用曲美他嗪治疗CHF患者,临床疗效明显,且能有效下调血清中BNF、IL-6的表达,无明显不良反应,值得临床积极应用.
展开▼
